Cannabigerol exerts in vivo and in vitro anti-inflammatory effects.
Cannabigerol ExertsandAnti-Inflammatory Effects via Inhibition of the MAPK and NF-κB Pathways.
AI Summary
Key Findings
Abstract
L. has a long history of use and contains more than 80 cannabinoids. However, although cannabigerol (CBG), which acts as a biosynthetic precursor of its most abundant phytocannabinoids, has anti-inflammatory effects, the exact mechanism of action remains underexplored. In this study, we explored the anti-inflammatory potential of CBG to assess its potential for therapeutic and industrial applications. CBG was extracted from the cannabis cultivar 'Pink Pepper'assays were performed via RAW 264.7 mouse macrophages stimulated with lipopolysaccharide, andefficacy was evaluated through a carrageenan-induced paw edema mouse model to confirm the activity of CBG in acute inflammation. Nitric oxide production, mRNA, and protein expression of inflammatory mediators were suppressed by CBG treatment in a process downregulated through the MAPK and NF-κB pathways. Although paw edema was not statistically significantly reduced, oral administration of CBG suppressed the expression of COX-2, iNOS, TNF-α, IL-1β, and IL-6 in the carrageenan-induced mouse model. CBG has been demonstrated to exert significant anti-inflammatory effects via modulation of key inflammatory mediators and signaling pathways in bothandmodels. Our findings further support the potential of CBG as a bioactive compound for further anti-inflammatory research.
Affiliation
Jong-Hui Kim
External References
- PubMed ID:
- 41423277
Comments
Sign in or create a free account to join the conversation.
Sign in to commentBe the first to comment.